5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.26▲ | 1.26▲ | 1.26▲ | 1.30▼ | 1.34▼ |
MA10 | 1.32▼ | 1.32▼ | 1.32▼ | 1.33▼ | 1.36▼ |
MA20 | 1.36▼ | 1.35▼ | 1.35▼ | 1.33▼ | 1.55▼ |
MA50 | 1.38▼ | 1.36▼ | 1.34▼ | 1.35▼ | 2.41▼ |
MA100 | 1.39▼ | 1.37▼ | 1.36▼ | 1.55▼ | 2.86▼ |
MA200 | 1.40▼ | 1.38▼ | 1.54▼ | 1.87▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.015▼ | -0.016▼ | -0.017▼ | -0.007▼ | 0.025▲ |
RSI | 37.584▼ | 40.400▼ | 41.738▼ | 42.427▼ | 40.157▼ |
STOCH | 4.040▼ | 3.652▼ | 3.652▼ | 21.104 | 17.347▼ |
WILL %R | -92.308▼ | -92.308▼ | -92.308▼ | -88.636▼ | -97.571▼ |
CCI | -88.963 | -89.011 | -88.889 | -93.841 | -64.917 |
Tuesday, April 16, 2024 09:40 AM
Silva Francisco, the VP of Research and Development of BioRestorative Therapies Inc, purchase 1,708 shares at $1.16 during a trade that took place back on Apr 08 ’24, which means that Silva Francisco ...
|
Tuesday, April 16, 2024 06:53 AM
Tuesday said that the U.S. Food and Drug Administration has cleared an amendment to the protocol of the ongoing Phase 2 study investigating the use of BRTX-100, the company’s lead cell therapy ...
|
Tuesday, April 16, 2024 06:45 AM
Amendment replaces saline injections with sham injections in the control group —MELVILLE, N.Y., April 16, 2024 (GLOBE NEWSWIRE) -- ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
26/04/24 | 1.26 | 1.26 | 1.26 | 1.26 | 0 |
25/04/24 | 1.23 | 1.28 | 1.21 | 1.23 | 61,996 |
24/04/24 | 1.35 | 1.36 | 1.25 | 1.27 | 83,814 |
23/04/24 | 1.38 | 1.41 | 1.335 | 1.34 | 89,272 |
22/04/24 | 1.39 | 1.42 | 1.35 | 1.38 | 60,226 |
19/04/24 | 1.41 | 1.45 | 1.3308 | 1.37 | 167,380 |
18/04/24 | 1.30 | 1.45 | 1.29 | 1.44 | 246,352 |
17/04/24 | 1.24 | 1.44 | 1.23 | 1.39 | 668,220 |
16/04/24 | 1.42 | 1.65 | 1.2618 | 1.31 | 10,718,606 |
15/04/24 | 1.3199 | 1.35 | 1.275 | 1.32 | 37,362 |
|
|
||||
|
|
||||
|
|